Home▸Andropause Testosterone Therapy▸Testosterone Therapy Cardiovascular Risk Simulator

👨 Testosterone Therapy Cardiovascular Risk Simulator

This simulation assesses the cardiovascular risks associated with testosterone therapy, including potential benefits and hazards for patients undergoing treatment.

Andropause Testosterone Therapy2DModerate60 FPS
Testosterone Therapy Cardiovascular Risk Simulator ↗ Open standalone

Historical FDA Warning on Testosterone and Cardiovascular Risk

Early observational signals prompted regulatory caution on TRT.

  • 2015: FDA warning added (Label update on CV risk)
  • 2013–2014: Trigger study (VA cohort & JAMA studies)
  • Disputed: Risk signal (Methodology criticized)
  • All TRT products: Label scope (Class-wide caution)

Regulatory background

Placeholder: brief history of the FDA safety communication on testosterone.

Studies that triggered concern

Placeholder: short note on the observational studies behind the warning.

Placeholder highlight: warning prompted more rigorous trials.

Conflicting Trial Evidence — the TRAVERSE Randomized Trial

TRAVERSE is the largest randomized CV safety trial of testosterone.

  • TRAVERSE: Trial name (Published 2023, NEJM)
  • ~5,200: Participants (Men with hypogonadism)
  • Non-inferior: Primary outcome (MACE vs placebo)
  • ~22 months: Duration (Mean follow-up)

Trial design summary

Placeholder: short description of TRAVERSE randomized design.

Reconciling earlier signals

Placeholder: short note on why earlier studies differed.

Placeholder highlight: no overall MACE increase found.

Hematocrit Elevation and Thrombosis Risk During Therapy

Testosterone stimulates erythropoiesis, raising hematocrit and viscosity.

  • ~5–15%: Erythrocytosis risk (Of treated patients)
  • 54%: Hct safety ceiling (Common threshold for pause)
  • 3–12 months: Onset (Typical time to elevation)
  • EPO ↑: Mechanism (Erythropoietin stimulation)

Mechanism of erythrocytosis

Placeholder: short note on testosterone-driven red cell increase.

Clot risk implications

Placeholder: short note on viscosity and thrombosis link.

Placeholder highlight: hematocrit is the key modifiable marker.

Baseline Cardiovascular Risk Stratification Before Therapy

Pre-therapy screening identifies patients needing closer monitoring.

  • ASCVD score: Screening tools (Plus history review)
  • Prior MI/stroke: High-risk flags (Recent CV events)
  • Recommended: Shared decision (Patient counseling step)
  • Uncontrolled CVD: Contraindication (Relative caution zone)

Stratification approach

Placeholder: short note on baseline risk categorization.

Shared decision-making

Placeholder: short note on counseling higher-risk candidates.

Placeholder highlight: individualized risk-benefit discussion matters.

Monitoring Protocol During Ongoing Testosterone Therapy

Scheduled labs track hematocrit, lipids, and CV symptoms over time.

  • 3, 6, 12 mo: Hct check (Then annually)
  • Annual: Lipid panel (Or as indicated)
  • Hct >54%: Action threshold (Dose adjust / pause)
  • Ongoing: Follow-up (Duration of therapy)

Monitoring schedule

Placeholder: short note on lab check cadence during TRT.

Response to abnormal values

Placeholder: short note on dose reduction or therapeutic phlebotomy.

Placeholder highlight: routine monitoring reduces avoidable risk.
⚙ Under the hood

This simulation assesses the cardiovascular risks associated with testosterone therapy, including potential benefits and hazards for patients undergoing treatment.

CanvasBiomedicine

2D · HTML5 Canvas 2D · 60 FPS target · runs fully client-side, no install

What did you find?

Add reproduction steps (optional)